fda stopping compounded semaglutide crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many Hims & Hers stock falls

This increases: hepatic fat oxidation energy expenditure triglyceride mobilization References: Habegger KM et al., Nature Medicine , 2010 Kim T et al., Cell Metabolism , 2018 Clinical Trial Evidence Obesity (Phase 2) Key outcomes: up to 24% body weight reduction majority of weight loss from fat mass Reference: Type 2 Diabetes Observed effects: HbA1c reduction improved glycemic control reduced insulin resistance Reference: Body Composition Effects Retatrutide appears to: reduce visceral adipose tissue reduce hepatic steatosis preserve lean mass when combined with resistance training Reference: Gastaldelli A et al., Diabetes , 2020 Neurological Research Context GLP-1 receptors are expressed in multiple brain regions including: hippocampus hypothalamus cortex These pathways may influence: neuroinflammation neuronal energy metabolism cognitive signaling Reference: Hlscher C, Nature Reviews Neuroscience , 2014 Cardiovascular and Renal Effects Incretin therapies have demonstrated: improved endothelial function reduced systemic inflammation lower cardiovascular risk markers Reference: Marso SP et al., NEJM , 2016 Safety and Tolerability Common adverse events in trials include: nausea vomiting diarrhea constipation These are generally dose-dependent and improve with titration

The cold constricts blood vessels and numbs the nerve endings, which can significantly reduce both swelling and itching

49 Our review includes a study by Wium-Andersen et al 34 proposing the association of GLP-1 agonist treatment with a reduced risk of alcohol-related events which include alcohol withdrawal syndrome and alcohol dependence

Lets break down what people are actually injecting: Retatrutide , developed by , is a triple agonist that hits Eli Lilly GLP-1 , GIP, and glucagon receptors